Bristol Myers Squibb (CELG-RI) Non-Current Deferred Tax Liability (2009 - 2026)

Bristol Myers Squibb has disclosed Non-Current Deferred Tax Liability across 15 years of filings, most recently posting $211.0 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability fell 23.55% year-over-year to $211.0 million; the TTM figure through Mar 2026 stood at $211.0 million (down 23.55% YoY), while the FY2025 annual figure was $222.0 million, down 95.14% from the prior year.
• Non-Current Deferred Tax Liability eased to $211.0 million in Q1 2026, from $222.0 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for CELG-RI reached as high as $4.9 billion in Q4 2023 and fell as low as $211.0 million in Q1 2026.
• The 5-year median for Non-Current Deferred Tax Liability is $461.0 million (2024), against an average of $1.6 billion.
• Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability surged 126.41% — and 2025, when it tumbled 95.14%.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $2.2 billion in 2022, then jumped by 126.41% to $4.9 billion in 2023, then decreased by 6.77% to $4.6 billion in 2024, then plunged by 95.14% to $222.0 million in 2025, then retreated by 4.95% to $211.0 million in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $211.0 million, $222.0 million, and $225.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.